Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antithymocyte globulin (rabbit) is a purified, pasteurized polyclonal antibody preparation derived from rabbits immunized with human T lymphocytes. It acts as an immunosuppressant by binding to multiple T-cell surface antigens, leading to the depletion of T lymphocytes through complement-mediated cytotoxicity and apoptosis. This results in suppression of the host immune response, making it effective for both prophylaxis and treatment of acute rejection in kidney transplant recipients. The drug is used in conjunction with other immunosuppressive agents and is administered intravenously[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antithymocyte globulin rabbit.